OMEROS CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
OMEROS CORP (OMER) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $6.94 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.05, a 145.43% increase year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.28, a 5.20% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.46.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.10, a 64.00% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $7.13, a 47.31% increase from fiscal 2024.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $4.84, a 18.05% increase from fiscal 2023.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $4.10, a 0.00% change from fiscal 2022.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $4.10, a 54.95% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.94 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $8.05 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $7.13 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $3.01 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $3.30 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $3.28 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $4.84 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $3.19 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $3.32 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $3.46 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $4.10 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $4.10 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $4.98 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $4.10 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $4.10 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $4.10 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $4.10 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $9.10 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $9.54 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $9.40 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $11.39 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $9.03 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $9.05 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $8.82 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $8.84 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $9.50 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $9.80 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $9.26 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $10.01 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $8.79 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $8.80 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $10.03 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $9.09 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $8.45 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $9.01 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $8.97 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $9.74 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $2.12 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $3.82 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $4.42 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $4.87 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $5.13 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $5.51 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $4.66 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $2.02 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $6.06 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $6.39 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $5.80 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $5.93 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $3.57 10-K · filed 2014-03-13 | |||
| 2013-09-30 | $1.29 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $1.31 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $1.68 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $3.64 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $3.93 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $3.59 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |